# Junhemeng Biopharmaceutical (Hangzhou)

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/junhemeng-biopharmaceutical-hangzhou

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.jhm-biopharma.com
- Total disclosed funding: $108M
- Latest round: Series C (Jun 8, 2026)
- Investors on record: 14

## About

Based in Hangzhou, China, and established in 2020, Junhe Alliance Biopharmaceutical (Hangzhou) Co., Ltd., trading as Junhemeng Biopharmaceutical (Hangzhou), is a biopharmaceutical company that focuses on the R&D of recombinant protein drugs. It established approximately 8,000 square meters of GMP-level production bases in Hangzhou. In June 2026, Junhemeng Biopharmaceutical (Hangzhou) raised CNY 200 million in series C co-led by Heda Venture, Harmony Venture, with participation from CS Capital and 3E Bioventures Capital, Guangdian Capital, Hongsheng Junhao Investment and other investors.
Junhemeng Biopharmaceutical (Hangzhou) developed recombinant protein R&D platforms, covering recombinant protein express systems, separation and purification technologies, protein in vitro folding and self-assembly systems, and drug Long-lasting slow-release control technologies. Products include recombinant human collagen, recombinant botulinum toxin type A, recombinant growth hormone, etc.
The company generates revenue by providing recombinant protein drugs.
The series C funds raised in this round of financing will be primarily used to continuously improve the company's pipeline of products under development, promote industrialization and commercialization, and further deepen the company's strategic layout in its focused areas.

## Funding rounds

- Series C, Jun 8, 2026, $30M — Harmony Venture, 3E Bioventures Capital, CS Capital, Hongsheng Junhao Investment, Guangdian Capital, Heda Venture
- Series B, Sep 10, 2024, $35M — Oriza Holdings, Beijing New Oxygen Technology Co., Ltd., SDIC Unity Capital, Hongsheng Junhao Investment
- Series A, Jan 16, 2023, $15M — 3E Bioventures Capital, Guangdian Capital
- Series A, Oct 8, 2022, $28M — Zhongtou Zhongcai Capital, Guangdian Capital, WinX Capital, Zhejiang Hongshi Private Equity Fund Management, Tonghua County State-owned Assets Investment Holding Group, Focus (Beijing) Private Equity Fund Management

## Investors

- Zhongtou Zhongcai Capital (https://capitalatlas.ai/funds/zhongtou-zhongcai-capital) — Series A
- Guangdian Capital (https://capitalatlas.ai/funds/guangdian-capital) — Series A, Series C
- WinX Capital — Series A
- Zhejiang Hongshi Private Equity Fund Management — Series A
- Tonghua County State-owned Assets Investment Holding Group — Series A
- Focus (Beijing) Private Equity Fund Management — Series A
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series A, Series C
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series B
- Beijing New Oxygen Technology Co., Ltd. — Series B
- SDIC Unity Capital (https://capitalatlas.ai/funds/sdic-unity-capital) — Series B
- Hongsheng Junhao Investment (https://capitalatlas.ai/funds/hongsheng-junhao-investment) — Series B, Series C
- Harmony Venture (https://capitalatlas.ai/funds/harmony-venture) — Series C
- CS Capital — Series C
- Heda Venture (https://capitalatlas.ai/funds/heda-venture) — Series C